The exam shows how your shoulder works, while a scan shows its parts

The exam links soreness to movement and strength

A clinician checks reach, strength and stiffness, then notes which motions hurt. The neck and nerves also need checking when soreness or numbness travels down the arm. Sudden weakness after an injury raises different concerns than a slow ache. What you can do matters when the clinician discusses care.

An X-ray mainly shows bones, joint space and signs of wear. An MRI can show muscles and tendons, the strong cords that join muscles to bones around the joint. Either scan may show wear in a shoulder that feels fine. The finding is useful only when it matches the exam and your daily trouble.

Less soreness does not prove that the shoulder rebuilt

Less soreness and easier movement are results you notice yourself. A change on an MRI is a separate result. You may feel better even when the shoulder looks the same on the later scan. Ask which result the care is meant to provide.

Keep notes on sleep, reaching and lifting so you can judge whether care helps. The exam may show weakness, the scan may suggest a cause, and some doubt may remain. That's common with shoulder soreness. At QC Kinetix, a medical provider, the person doing your exam, may discuss care that uses concentrated blood parts in the sore shoulder.

Sources

1. In a nationally representative Finnish population sample of 602 adults aged 41-76 who had bilateral 3-Tesla shoulder MRI regardless of symptoms, rotator cuff abnormalities were found in 98.7% of participants (25% tendinopathy, 62% partial-thickness tear, 11% full-thickness tear). Abnormalities were present in 96% of ASYMPTOMATIC shoulders. Only full-thickness tears were more common in symptomatic shoulders, and that difference all but disappeared after adjustment (absolute difference 0.8%, 95% CI -3.4% to 6.0%).

   Ibounig T, et al. — Incidental Rotator Cuff Abnormalities on Magnetic Resonance Imaging.. JAMA Intern Med, 2026. DOI: 10.1001/jamainternmed.2025.7903.

2. The August 2025 AAOS Evidence-Based Clinical Practice Guideline on Management of Rotator Cuff Injuries issued 25 recommendations and 4 consensus statements. Among its updates it clearly RESTRICTS the use of platelet-rich plasma and marrow stimulation in rotator cuff repair, limits prolotherapy in full-thickness tears, establishes CT as an adjunctive imaging modality, and endorses early mobilization after repair of small-to-medium tears.

   Ye Y, et al. — [Interpretation of the 2025 American Academy of Orthopaedic Surgeons (AAOS) on Management of Rotator Cuff Injuries Evidence-Based Clinical Practice Guideline].. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2026. DOI: 10.7507/1002-1892.202511084.

3. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

4. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

5. A systematic review of the discordance between clinical and radiographic knee osteoarthritis: many people with severe-looking x-rays have little pain, and many with disabling pain have modest radiographic change. This is the reason a post-treatment scan is a poor proxy for how someone feels, in either direction.

   Bedson J, et al. — The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature.. BMC musculoskeletal disorders, 2008. DOI: 10.1186/1471-2474-9-116.

6. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, 2024.

7. The SUMMIT randomized trial treated 144 patients (mean age 33.8, mean lesion 4.8 cm2) with at least one symptomatic focal cartilage defect (Outerbridge III/IV, >=3 cm2) of the femoral condyle or trochlea. Matrix-applied characterized autologous cultured chondrocytes (MACI) improved KOOS pain (37.0 to 82.5) and function significantly more than microfracture (pain 35.5 to 70.9) at 2 years, with histological and MRI assessment of the repair tissue. This is what a positive cartilage-repair trial looks like - in young patients with a discrete hole, not a worn joint.

   Saris D, et al. — Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial.. The American journal of sports medicine, 2014. DOI: 10.1177/0363546514528093.

8. A randomized, double-blind, placebo-controlled trial in a Japanese population tested leukocyte-POOR PRP specifically in mild-to-moderate knee OA WITH joint effusion or bone marrow lesions - i.e. a selected inflammatory phenotype rather than all comers. Recorded here because phenotype selection, not the product, is the most plausible explanation for why PRP trials disagree with one another.

   Yoshioka T, et al. — The Effectiveness of Leukocyte-Poor Platelet-Rich Plasma Injections for Symptomatic Mild to Moderate Osteoarthritis of the Knee With Joint Effusion or Bone Marrow Lesions in a Japanese Population: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.. The American journal of sports medicine, 2024. DOI: 10.1177/03635465241263073.